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Genetic deficiency in tissue kallikrein activity in mouse and
man: effect on arteries, heart and kidney
Abstract
Tissue kallikrein (KLK1) is a kinin-forming serine protease synthesized in many organs including
arteries and kidney. Study of the physiological role of KLK1 has benefited from the availability of
mouse and human genetic models of KLK1 deficiency, through engineering of KLK1 mouse mutants
and discovery of a major polymorphism in the human KLK1 gene that induces a loss of enzyme activity.
Studies in KLK1-deficient mice and human subjects partially deficient in KLK1 have documented its
critical role in arterial function in both species. KLK1 is also involved in the control of ionic transport in
the renal tubule, an action that may not be kinin-mediated. Studies of experimental diseases in
KLK1-deficient mice have revealed cardio- and nephro-protective effects of KLK1 and kinins in acute
cardiac ischemia, post-ischemic heart failure, and diabetes. Potential clinical and therapeutic
developments are discussed.
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Abstract
Tissue kallikrein (KLK1) is a kinin-forming serine protease
synthesized in many organs including arteries and kid-
ney. Study of the physiological role of KLK1 has benefit-
ed from the availability of mouse and human genetic
models of KLK1 deficiency, through engineering of KLK1
mouse mutants and discovery of a major polymorphism
in the human KLK1 gene that induces a loss of enzyme
activity. Studies in KLK1-deficient mice and human sub-
jects partially deficient in KLK1 have documented its crit-
ical role in arterial function in both species. KLK1 is also
involved in the control of ionic transport in the renal
tubule, an action that may not be kinin-mediated. Studies
of experimental diseases in KLK1-deficient mice have
revealed cardio- and nephro-protective effects of KLK1
and kinins in acute cardiac ischemia, post-ischemic heart
failure, and diabetes. Potential clinical and therapeutic
developments are discussed.
Keywords: cardiac ischemia; diabetic nephropathy;
endothelial function; heart failure; ion transport;
vasodilatation.
Introduction
Tissue kallikrein (KLK1) is a serine protease displaying
favourable kinetic parameters for hydrolysis of kinino-
gens, and is a major kinin-forming enzyme in mammals.
The pharmacological effects of kinins have been well
described at the systemic and cellular levels, and their
target organs have been identified (Bhoola et al., 1992).
Kinins are especially active on the vascular endothelium,
where they trigger release of several paracrine and auto-
crine mediators, such as NO, prostanoids and leuko-
trienes, and so-called hyperpolarizing factors, which
promote smooth muscle cell relaxation and inhibit plate-
let adhesion and aggregation (Leeb-Lundberg et al.,
2005). Through the action of these mediators, kinins are
potent vasodilators and inhibitors of blood coagulation.
In addition, kinins promote fibrinolysis by stimulating
release of tissue plasminogen activator from the endo-
thelium (Brown et al., 2000).
However, it is still largely unknown whether kinins are
released in vivo at tissue sites and in the circulation and
are involved in the control of homeostasis. The physio-
logical role of endogenously produced kinins has been
probed indirectly using angiotensin-converting enzyme
(ACE, kininase II, a major kinin-inactivating enzyme)
inhibitors, and directly using kinin receptor antagonists
and, more recently, kinin B2 receptor-deficient mice
(Borkowski et al., 1995; Linz et al., 1995). These phar-
macological and genetic tools have provided valuable
information, alone and in combination with ACE inhibi-
tors, especially in pathological situations. However, kinins
act on two types of receptors, B1 and B2. The B2 recep-
tor is constitutively synthesized in tissues, contrary to the
B1 receptor, and is generally considered as being the
receptor involved in the main effects of kinins in healthy
animals, including the vascular effects (Leeb-Lundberg et
al., 2005). But there is now evidence that the B1 receptor
is induced in the absence of the B2 receptor and takes
over functions of the latter, at least in arteries and heart
(Duka et al., 2001; Griol-Charhbili et al., 2005). Thus, the
role of kinins in homeostasis cannot be fully assessed
using B2 receptor-deficient mice. In addition, the mech-
anisms of kinin formation in tissues and the regulation of
this formation cannot be followed at the receptor level.
Recently, murine and human genetic models of KLK1
deficiency have become available through engineering of
KLK1 mouse mutants and discovery of a major poly-
morphism of the human KLK1 gene that induces a loss
of enzyme activity (Meneton et al., 2001; Slim et al.,
2002). Studies of kinin formation in KLK1-deficient mice
indicated that KLK1 is the main kinin-forming enzyme in
most organs, including arteries and kidney, in normal ani-
mals (Bergaya et al., 2001; Meneton et al., 2001). Phys-
iological studies in KLK1-deficient mice and in human
subjects partially deficient in KLK1 have revealed the crit-
ical role of KLK1 in arterial function in both species. Stud-
ies of experimental diseases in KLK1-deficient mice have
identified a cardioprotective role of KLK1 and kinins in
acute cardiac ischemia and post-ischemic heart failure,
and a nephroprotective role of KLK1 in diabetes. In addi-
tion, study of kidney function in KLK1-deficient mice and
man has suggested that KLK1 participates in the control
of ionic transport in the renal tubule, and that this action
may not be kinin-mediated.
KLK1 gene inactivation in the mouse
Disruption of the KLK1 gene in the mouse results in a
G95% reduction in kinin-forming activity on kininogen in
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kidney, colon, pancreas, and salivary glands of homo-
zygous KLK1-deficient mice (KLK1-/- mice). For the
salivary gland, which has 100- to 1000-fold more kinin-
forming activity than the other organs, 98% suppression
of activity was observed in KLK1-/- mice, despite high
abundance of several other proteases of the kallikrein
family in this organ. In kidney, pancreas and urine, kinin-
forming activity is virtually absent in KLK1-/- mice and is
30–40% of the wild-type level in heterozygous animals.
These observations suggest that in healthy animals,
KLK1 is the main kinin-forming enzyme in these organs
and is probably the only one of physiological relevance
(Meneton et al., 2001).
The KLK1 gene is expressed in arteries of wild-type
mice. When the carotid artery of these mice was per-
fused with kininogen, vasodilatation was observed that
was abolished by a kinin B2 receptor antagonist. In
KLK1-deficient mice, however, kininogen no longer dilat-
ed the artery (Bergaya et al., 2001). These observations
document the presence and functionality of KLK1 in
arteries and suggest that KLK1 is the sole kinin-forming
enzyme synthesized by these vessels.
Deficiency in KLK1 activity in humans
Early work suggested that the large inter-individual vari-
ability in urinary KLK1 (uKLK1) activity in man reflected,
at least in part, a genetic polymorphism of this activity.
Family studies revealed familial aggregation of uKLK1,
and proposed a transmission model for uKLK1, with a
major gene effect accounting for almost half of the vari-
ance of the trait (Zinner et al., 1976; Berry et al., 1989).
However, the molecular basis of the genetic polymor-
phism of uKLK1 remained unknown.
When the KLK1 gene on chromosome 19q13.2-q13.4
was studied, it was found that this gene and its promoter
were highly polymorphic. A complex, multi-allelic pro-
moter variation has been considered to be a candidate
for the genetic polymorphism of uKLK1, because this
promoter variation was reported to be associated with
blood pressure level, an observation also made for
uKLK1 in the family transmission studies (Yu et al., 2002).
However, association of this promoter variation with
uKLK1 has not been reported. On the other hand, several
single nucleotide polymorphisms were identified in the
coding sequence of the KLK1 gene, in the promoter and
the first intron (Slim et al., 2002). Two of these sequence
variations are non-synonymous substitutions in exon 3
and change an amino acid in KLK1, either in position 53
(the minor allele coding for histidine instead of arginine)
or in position 121 (glutamate instead of glutamine). Inter-
estingly, the R53H polymorphism was associated with a
decrease of approximately 50% in uKLK1 in several pop-
ulations in which only heterozygote subjects were iden-
tified. Furthermore, when recombinant kallikrein variants
were synthesized, the R53H variant displayed a defect in
enzyme activity. This defect was substrate-dependent,
but very pronounced for hydrolysis of kininogen, with
residual kinin-forming activity of -1% of the activity of
the wild-type enzyme (Slim et al., 2002).
KLK1 has an extended active site compared to other
kallikrein-related proteases that allows it to accommo-
date kininogens. Construction of a molecular model
based on crystallographic data suggests that the arginine
in position 53 is located in a putative kininogen-binding
subsite in the active site. This suggests a mechanistic
hypothesis for the inactivating effect of the R53H muta-
tion, which alters molecular structure and electrostatic
charge at this subsite. On the other hand, the Q121E
mutation was not associated with any significant varia-
tion in KLK1 activity, either in vitro or in vivo. The amino
acid in position 121 is located on the opposite side of
the molecule to the active site (Slim et al., 2002).
The allelic frequency of the R53H mutation is 0.03 in
European and 0.07 in African-Caribbean populations.
This implies that in European and North American pop-
ulations, 6–7% of subjects are heterozygous for this
mutation (Slim et al., 2002). Homozygous 53H subjects
should account for approximately 1:2000 individuals in
these populations, and none have been available for
study so far. Because of its low frequency, the R53H
mutation is unlikely to account for all of the genetic poly-
morphism of uKLK1, which was estimated to account for
more than 50% of the variance of uKLK1 in familial trans-
mission studies (Berry et al., 1989). Other genetic varia-
tions in KLK1 or other genes that are as yet unidentified
may also be involved. However, other polymorphisms
identified in KLK1 were not associated with uKLK1,
except for promoter variations that were in linkage dis-
equilibrium with the R53H polymorphism. In any case,
R53H subjects, with a 50% decrease in KLK1 activity,
can be studied to probe the physiological role of KLK1
in humans and to determine the consequences of partial
genetic deficiency in KLK1.
Arterial dysfunction in KLK1-deficient mice
and humans
KLK1-deficient mice have normal blood pressure at rest,
but arterial function is impaired in these mice, with abnor-
mal vasomotor response to blood flow. The mice display
a major defect in flow-dependent vasodilatation, a fun-
damental feature of arterial physiology that ensures prop-
er delivery of blood to tissues. At high blood flow,
vasodilatation is decreased by 40% in KLK1-/- mice,
whereas at low flow a paradoxical vasoconstrictor
response to flow increase is observed (Bergaya et al.,
2001; Meneton et al., 2001). This defect is observed in
both capacitance and resistance arteries (Hilgers et al.,
2003; Bergaya et al., 2004b). Flow-mediated vasodilata-
tion is an endothelium-dependent process, and these
observations are indicative of endothelial dysfunction in
KLK1-deficient mice, even if the vasodilator response to
exogenous acetylcholine is not altered (Bergaya et al.,
2001, 2004a,b). Interestingly, heterozygote mice with only
partial deficiency of KLK1 also exhibited a defect in flow-
dependent vasodilatation, an observation suggesting
that the level of KLK1 is a determinant of arterial function
(Bergaya et al., 2001).
To test extrapolation of these mouse findings to man,
the brachial artery of young human subjects carrying a
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mutated R53H allele and partially deficient in KLK1 was
studied non-invasively. These subjects, like the KLK1-
deficient mice, exhibited arterial abnormalities (Azizi et
al., 2005). Although flow-dependent dilatation was not
grossly impaired, shear stress was increased. Moreover,
although elevated shear stress should induce vasodila-
tation, a paradoxical narrowing of the artery lumen was
observed (Azizi et al., 2005). These functional abnormal-
ities are suggestive of endothelial dysfunction, even if, as
in the mouse, the vasodilator response to exogenous
acetylcholine was not altered (Azizi et al., 2005; Rossi et
al., 2006). These observations document the occurrence
of a new mild form of arterial dysfunction in heterozygous
subjects carrying the R53H KLK1mutation. As discussed
above, these subjects represent a significant subset (7%)
of European and North American populations.
These studies demonstrate that KLK1 is involved in
arterial function in both mouse and man. Whereas KLK1
levels are low in arteries compared to several other
organs that synthesize KLK1, the role of KLK1 appears
to be critical for arterial function. The action of KLK1 in
artery is most likely kinin- and B2 receptor-mediated. The
mechanism linking flow to KLK1 remains poorly under-
stood. As the vasomotor response to flow occurs quickly,
an effect on KLK1 gene transcription and KLK1 synthesis
is unlikely, at least initially. An increase in shear stress
may trigger addressing of KLK1 to the endothelial cell
surface, where it can access its substrate, kininogen,
which is present in plasma and adsorbed on endothelial
cell surfaces (Hasan et al., 1995). Shear stress may also
increase the accessibility of kinins to endothelial B2
receptors.
In any case, the arterial dysfunction of R53H subjects
may increase their risk of developing cardiovascular dis-
eases with aging or in pathological settings such as dia-
betes. This hypothesis needs to be tested in population
studies. Study of the KLK1-deficient mouse may also
provide information relevant to a putative causal link
between KLK1 deficiency and cardiovascular diseases.
This has been the case so far for ischemic heart disease.
Effects of KLK1 deficiency in the normal
and ischemic heart
The heart of KLK1-deficient mice is either normal or
exhibits minor functional and trophic abnormalities,
depending on the genetic background. On a mixed
129sv-C57BL6 background, mostly 129sv, the heart
exhibits mild thinning of the septum and posterior wall
and a tendency to dilatation in comparison to wild-type
littermates (Meneton et al., 2001). When the KLK1 gene-
inactivating mutation was developed on a pure C57BL6
background, however, the heart did not exhibit any func-
tional or trophic abnormality (Trabold et al., 2002). A sim-
ilar differential effect of these two genetic backgrounds
on cardiac phenotype has been observed for B2 recep-
tor-deficient mice (Madeddu et al., 2007). Mice of the 129
strain have two renin genes, contrary to those of the
C57BL6 strain, which have only one renin gene. It has
been hypothesized that activation of the renin-angioten-
sin system explains enhanced blood pressure and car-
diac sensitivity to physiological stimulus in 129 mice
(Wang et al., 2002), although this has not been consis-
tently observed (Gurley et al., 2006). Blood pressure in
KLK1-deficient mice is normal on all genetic back-
grounds studied. It may nevertheless be speculated that
the coronary arteries of KLK1-deficient mice have, like
other arteries, endothelial dysfunction, resulting in abnor-
mal regulation of coronary blood flow and subsequent
cardiac adaptation and remodeling, since the heart is a
permanently working organ that is highly sensitive to
blood supply. However, dysregulation of coronary blood
flow may remain moderate under basal conditions and
cardiac remodeling is only observed on a permissive
genetic background.
In the C57BL6 strain with one renin gene, the heart of
KLK1-/- mice is morphologically and functionally indistin-
guishable from the heart of wild-type littermates. This
strain was thus used to study experimental cardiac
diseases, allowing straightforward interpretation of the
effect of KLK1 mutation on disease-related phenotypes.
In the setting of acute cardiac ischemia and ischemia
reperfusion injury, KLK1-deficient mice exhibit a defect in
cardioprotective mechanisms preventing necrosis, as
evidenced by a severe decrease in the beneficial effect
of ischemic preconditioning (Griol-Charhbili et al., 2005).
Ischemic preconditioning is an experimental maneuver
consisting of repeated short cycles of ischemia reperfu-
sion before inducing prolonged ischemia. It activates a
number of cardiac protective mechanisms, which are
only partly understood, resulting in infarct size reduction.
Although the clinical relevance of ischemic precondition-
ing cannot be established easily, this phenomenon is
believed to occur in man in coronary insufficiency and to
play a significant role in disease outcome, protecting
against myocardial infarction. KLK1-deficient mice exhib-
ited a 40% decrease in the effect of ischemic precondi-
tioning (Griol-Charhbili et al., 2005). In addition, in the
setting of acute cardiac ischemia and ischemia-reperfu-
sion injury, the well-documented infarct size-limiting
effect of ACE inhibitors and of angiotensin II AT1 receptor
antagonists is almost completely suppressed in KLK1-
deficient mice (Griol-Charhbili et al., 2005; Messadi-Laribi
et al., 2007). These data indicate that the cardioprotective
effect of these drugs in acute cardiac ischemia in mouse
requires KLK1, and is mainly, if not entirely, mediated by
kinins. The hypothesis of a prominent role of kinins in the
cardioprotective effects of ACE inhibitors relies on a well-
established physiological pathway (inactivation of kinins
by ACE) and has been previously documented using B2
receptor antagonists and B2 receptor-deficient mice (Linz
et al., 1995; Yang et al., 2001), but the role of KLK1 in
the effect of angiotensin II AT1 receptor antagonists
appears more surprising. This issue is discussed below.
In post-ischemic heart failure induced by coronary lig-
ature and myocardial infarction, KLK1 deficiency is also
detrimental. It aggravates cardiac remodeling and
decreases survival, especially after several months of
evolution (Pons et al., 2008).
Overall, these studies point to a major cardioprotective
role of KLK1 in acute cardiac ischemia and heart failure.
The effect of KLK1 deficiency can be mimicked by B2
receptor blockade, at least in acute ischemia (Griol-
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Charhbili et al., 2005), and therefore the effects of KLK1
in the ischemic heart are most probably kinin-mediated.
Kinins influence coronary perfusion, cardiac metabolism
and redox status (Oldenburg et al., 2004). In post-ische-
mic heart failure, NO synthase isoforms seem to be
involved in KLK1 and kinin effects (Pons et al., 2008).
These studies establish KLK1 as the major kinin-forming
enzyme in the ischemic heart. The observations in KLK1-
deficient mice raise the hypothesis that KLK1-deficient
subjects may be at increased risk of myocardial infarction
in coronary heart disease, with poorer prognosis in heart
failure. This hypothesis needs to be tested in clinical
studies. It is of interest that the well-documented genetic
polymorphism of ACE levels has been linked to the risk
of myocardial infarction (Cambien et al., 1992, 1994). As
high ACE levels, like KLK1 deficiency, induce kinin deple-
tion, the observation of a loss of the beneficial effect of
ischemic preconditioning in KLK1-deficient mice sug-
gests a mechanistic hypothesis for the association of
ACE levels with myocardial infarction risk. Indeed, a pre-
liminary study indicated that in mice bearing a duplication
of the ACE gene, the effect of ischemic preconditioning
was suppressed (Richer and Alhenc-Gelas, unpublished
data).
Role of KLK1 in the cardiovascular effects
of angiotensin II AT2 receptor stimulation
Although the angiotensin II AT2 receptor is involved in
flow-dependent dilatation in normal mice and its inhibi-
tion impairs relaxation, in KLK1-/- mice this receptor is
normally present, but its inhibition has no effect (Bergaya
et al., 2004a). Conversely, inhibition of the B2 receptor
reduces flow-dependent dilatation in normal mice, but
has no effect in AT2 receptor-deficient mice. These
observations suggest a functional coupling between the
AT2 receptor and KLK1 and kinins in arteries. Coupling
between the AT2 and B2 receptors has previously been
proposed in the kidney, heart and arteries on the basis
of pharmacological experiments with B2 receptor antag-
onists that suppressed some of the effects of AT1 recep-
tor blockade, a maneuver that induces AT2 receptor
stimulation (Gohlke et al., 1998; Sato et al., 2000; Siragy
et al., 2000). However, the mechanism of this physiolog-
ical coupling remains unclear, and both kinin- and non-
kinin-mediated mechanisms have been postulated
(Abadir et al., 2006; Messadi-Laribi et al., 2007). Studies
in KLK1-deficient mice indicate that KLK1 is involved in
the coupling between AT2 and B2 receptors in arteries
(Bergaya et al., 2004a). Observations in the ischemic
heart during AT1 receptor blockade (see above, Messadi-
Laribi et al., 2007) also support the hypothesis that AT2
receptor stimulation triggers kinin formation by KLK1 and
subsequent B2 receptor activation. KLK1 might also
directly activate the B2 receptor (Hecquet et al., 2000).
Thus, the renin angiotensin system is positively cou-
pled to the tissue kallikrein-kinin system through the AT2
receptor. This pathway is activated when AT1 receptor
function is suppressed, and is involved in arterial vaso-
dilatation and in cardioprotection during ischemia. The
physiological role of the AT2-KLK1-B2 pathway in the
presence of a functional AT1 receptor remains to be
established.
Effect of KLK1 deficiency in the kidney:
kinin- and non-kinin-mediated effects
KLK1 in renal arteries is likely to participate in the control
of renal hemodynamics. However, KLK1 is also synthe-
sized in abundance in renal epithelial cells in the distal
tubule and is secreted in urine. The function of epithelial
KLK1 in the kidney remains unknown. In a systematic
study of water and electrolyte metabolism, it was
observed that KLK1-deficient mice displayed hypercal-
ciuria of renal origin and were unable to maintain normal
plasma calcium level when submitted to a calcium-poor
regimen because of persistent urinary calcium loss
(Picard et al., 2005). Interestingly, the renal calcium
defect of KLK1-deficient mice was not observed in B2
receptor-deficient mice, even after treatment with a B1
receptor antagonist (Picard et al., 2005). This suggests a
non-kinin-mediated mechanism for the effect of KLK1 on
calcium reabsorption. A proteolytic effect of KLK1 on
proteins involved in calcium transport in distal tubular
cells can be hypothesized. Proteolytic regulation of elec-
trolytes transport in the kidney tubule has already been
documented for other proteases (Vallet et al., 1997).
KLK1 partly co-localizes with the calcium transporter
TRPV5 in the distal tubule (Picard et al., 2005). In primary
culture of renal calcium-transporting epithelial cells,
KLK1 is able to increase calcium reabsorption by stabi-
lizing TRPV5 on the plasma membrane. However, this in
vitro effect of KLK1 has been reported to be kinin- and
B2 receptor-mediated (Gkika et al., 2006). Thus, although
observations in KLK1-deficient mice indicate that renal
KLK1 is involved in calcium reabsorption in the distal
tubule, it is not clear at present whether this action is
direct or kinin-mediated or both. Recent data obtained in
KLK1-deficient mice also suggest that KLK1 is involved
in proteolytic regulation of the sodium channel Enac in
the renal tubule (Picard et al., 2008). The involvement of
KLK1 in renal calcium metabolism has been confirmed in
man by studying partially KLK1-deficient subjects. A
minor defect in renal calcium reabsorption, evidenced by
furosemide administration, has indeed been observed in
these subjects (Blanchard et al., 2007).
A circulating form of KLK1 is present in plasma.
Although plasma KLK1 in mouse is believed to originate
mainly from the salivary glands, which are well developed
in this species, indirect evidence suggests that plasma
KLK1 in man originates mainly from the kidney (Azizi et
al., 2008). Plasma KLK1 is regulated by sodium and
potassium intake. The role of this endocrine component
of the renal kallikrein-kinin system in the control of homeo-
stasis remains unknown. KLK1 irreversibly binds prote-
ase inhibitors in plasma (Zhou et al., 1992). However, this
binding is a slow process, and before inactivation plasma
KLK1 may produce kinins near its secretion site, or at
distance, although this is speculative.
An investigation of experimental renal diseases in
KLK1-deficient mice is currently in progress. KLK1 defi-
ciency aggravates diabetic nephropathy (Bodin, Alhenc-
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Gelas and Bouby, unpublished data). This observation is
in agreement with previous studies documenting aggra-
vation of the disease in mice bearing a duplication of the
ACE gene (Huang et al., 2001) and in those with inacti-
vation of the B2 receptor gene (Kakoki et al., 2006).
Kinins seem to play a major role in protection against
organ damage in the kidney and the cardiovascular sys-
tem in the setting of diabetes.
Conclusions
The availability of mutant mice and human subjects
genetically deficient in KLK1 activity has allowed recog-
nition of the importance of KLK1 and its kinin peptide
products in arterial function in both species, which was
largely unsuspected from previous studies. KLK1
appears to be the major kinin-forming enzyme in arteries,
heart and kidney. The KLK1-deficient mouse can be con-
sidered practically as a kinin-free mouse, at least in nor-
mal condition and in the pathological situations studied,
cardiac ischemia and insulin-dependent diabetes. In
these pathological situations, the tissue kallikrein-kinin
system is involved in heart and kidney protection and its
absence aggravates cardiac necrosis and renal damage.
The clinical relevance of observations in KLK1-deficient
mice can be tested by studying cardiac and renal dis-
eases in partially KLK1-deficient human subjects.
Studies have also documented the involvement of
KLK1 in the regulation of electrolyte transport in the kid-
ney tubule, but in this case KLK1 action may not be
kinin-mediated. The recent availability of mice with com-
bined inactivation of the B1 and B2 receptors (Cayla et
al., 2007; Kakoki et al., 2007) may help to clarify the issue
of kinin- versus non-kinin-mediated physiological action
of KLK1.
Data obtained in mouse and man deficient in KLK1
further support the concept of the kallikrein-kinin system
as a promising therapeutic target. Therapeutic activation
of this system is currently achieved indirectly and only
mildly using ACE inhibitors or angiotensin II AT1 receptor
antagonists, an approach that is efficacious in a number
of cardiovascular and renal diseases. However, the ther-
apeutic efficacy of ACE inhibitors and AT1 receptor
blockers is probably restricted by the limited availability
of endogenous KLK1 and kinins. The design and evalu-
ation of more potent pharmacological interventions
based on kinin receptor agonism are warranted.
Acknowledgments
This work was supported by Institut National de la Sante´ et de
la Recherche me´dicale, Paris-Descartes University, the Europe-
an Vascular Genomics Network, a Network of Excellence sup-
ported by the European Community’s 6th Framework Program
for Research Priority 1 ‘Life sciences, genomics and biotech-
nology for health’ (contract no. LSHM-CT-2003-503254), and by
the National Research Agency (grant ANR 05-PCOD-027).
References
Abadir, P.M., Periasamy, A., Carey, R.M., and Siragy, H.M.
(2006). Angiotensin II type 2 receptor-bradykinin B2 receptor
functional heterodimerization. Hypertension 48, 316–322.
Azizi, M., Boutouyrie, P., Bissery, A., Agharazii, M., Verbeke, F.,
Stern, N., Bura-Riviere, A., Laurent, S., Alhenc-Gelas, F., and
Jeunemaitre, X. (2005). Arterial and renal consequences
of partial genetic deficiency in tissue kallikrein activity in
humans. J. Clin. Invest. 115, 780–787.
Azizi, M., Emanueli, C., Peyrard, S., Madeddu, P., Alhenc-Gelas,
F., and Campbell, D. (2008). Genetic and dietary control of
plasma tissue kallikrein secretion and urinary kinins excretion
in man. J. Hypertens. 26, 714–720.
Bergaya, S., Meneton, P., Bloch-Faure, M., Mathieu, E., Alhenc-
Gelas, F., Levy, B.I., and Boulanger, C.M. (2001). Decreased
flow-dependent dilation in carotid arteries of tissue kallikrein-
knockout mice. Circ. Res. 88, 593–599.
Bergaya, S., Hilgers, R.H., Meneton, P., Dong, Y., Bloch-Faure,
M., Inagami, T., Alhenc-Gelas, F., Levy, B.I., and Boulanger,
C.M. (2004a). Flow-dependent dilation mediated by endo-
genous kinins requires angiotensin AT2 receptors. Circ. Res.
94, 1623–1629.
Bergaya, S., Matrougui, K., Meneton, P., Henrion, D., and Bou-
langer, C.M. (2004b). Role of tissue kallikrein in response to
flow in mouse resistance arteries. J. Hypertens. 22, 745–750.
Berry, T.D., Hasstedt, S.J., Hunt, S.C., Wu, L.L., Smith, J.B., Ash,
K.O., Kuida, H., and Williams, R.R. (1989). A gene for high
urinary kallikrein may protect against hypertension in Utah
kindreds. Hypertension 13, 3–8.
Bhoola, K.D., Figueroa, C.D., and Worthy, K. (1992). Bioregula-
tion of kinins, kallikreins, kininogens, and kininases. Phar-
macol. Rev. 44, 1–80.
Blanchard, A., Azizi, M., Peyrard, S., Stern, N., Alhenc-Gelas, F.,
Houillier, P., and Jeunemaitre, X. (2007). Partial human genet-
ic deficiency in tissue kallikrein activity and renal calcium
handling. Clin. J. Am. Soc. Nephrol. 2, 320–325.
Borkowski, J.A., Ransom, R.W., Seabrook, G.R., Trumbauer, M.,
Chen, H., Hill, R.G., Strader, C.D., and Hess, J.F. (1995). Tar-
geted disruption of a B2 bradykinin receptor gene in mice
eliminates bradykinin action in smooth muscle and neurons.
J. Biol. Chem. 270, 13706–13710.
Brown, N.J., Gainer, J.V., Murphey, L.J., and Vaughan, D.E.
(2000). Bradykinin stimulates tissue plasminogen activator
release from human forearm vasculature through B2 receptor-
dependent, NO synthase-independent, and cyclooxygenase-
independent pathway. Circulation 102, 2190–2196.
Cambien, F., Poirier, O., Lecerf, L., Evans, A., Cambou, J.P.,
Arveiler, D., Luc, G., Bard, J.M., Bara, L., Ricard, S., et al.
(1992). Deletion polymorphism in the gene for angiotensin-
converting enzyme is a potent risk factor for myocardial-
infarction. Nature 359, 641–644.
Cambien, F., Costerousse, O., Tiret, L., Poirier, O., Lecerf, L.,
Gonzales, M.F., Evans, A., Arveiler, D., Cambou, J.P., Luc, G.,
et al. (1994). Plasma-level and gene polymorphism of angio-
tensin-converting enzyme in relation to myocardial-infarction.
Circulation 90, 669–676.
Cayla, C., Todiras, M., Iliescu, R., Saul, V.V., Gross, V., Pilz, B.,
Chai, G., Merino, V.F., Pesquero, J.B., Baltatu, O.C., and
Bader, M. (2007). Mice deficient for both kinin receptors are
normotensive and protected from endotoxin-induced hypo-
tension. FASEB J. 21, 1689–1698.
Duka, I., Kintsurashvili, E., Gavras, I., Johns, C., Bresnahan, M.,
and Gavras, H. (2001). Vasoactive potential of the B1 bra-
dykinin receptor in normotension and hypertension. Circ.
Res. 88, 275–281.
Gkika, D., Topala, C.N., Chang, Q., Picard, N., Thebault, S.,
Houillier, P., Hoenderop, J.G., and Bindels, R.J. (2006). Tissue
kallikrein stimulates Ca2q reabsorption via PKC-dependent
plasma membrane accumulation of TRPV5. EMBO J. 25,
4707–4716.
706 A. Pizard et al.
Article in press - uncorrected proof
Gohlke, P., Pees, C., and Unger, T. (1998). AT2 receptor stimu-
lation increases aortic cyclic GMP in SHRSP by a kinin-
dependent mechanism. Hypertension 31, 349–355.
Griol-Charhbili, V., Messadi-Laribi, E., Bascands, J.L., Heudes,
D., Meneton, P., Giudicelli, J.F., Alhenc-Gelas, F., and Richer,
C. (2005). Role of tissue kallikrein in the cardioprotective
effects of ischemic and pharmacological preconditioning in
myocardial ischemia. FASEB J. 19, 1172–1174.
Gurley, S.B., Allred, A., Le, T.H., Griffiths, R., Mao, L., Philip, N.,
Haystead, T.A., Donoghue, M., Breitbart, R.E., Acton, S.L.,
et al. (2006). Altered blood pressure responses and normal
cardiac phenotype in ACE2-null mice. J. Clin. Invest. 116,
2218–2225.
Hasan, A.A., Cines, D.B., Ngaiza, J.R., Jaffe, E.A., and Schmaier,
A.H. (1995). High-molecular-weight kininogen is exclusively
membrane bound on endothelial cells to influence activation
of vascular endothelium. Blood 85, 3134–3143.
Hecquet, C., Tan, F., Marcic, B.M., and Erdos, E.G. (2000).
Human bradykinin B2 receptor is activated by kallikrein and
other serine proteases. Mol. Pharmacol. 58, 828–836.
Hilgers, R.H., Bergaya, S., Schiffers, P.M., Meneton, P., Boulan-
ger, C.M., Henrion, D., Levy, B.I., and De Mey, J.G. (2003).
Uterine artery structural and functional changes during preg-
nancy in tissue kallikrein-deficient mice. Arterioscler. Thromb.
Vasc. Biol. 23, 1826–1832.
Huang, W., Gallois, Y., Bouby, N., Bruneval, P., Heudes, D.,
Belair, M.F., Krege, J.H., Meneton, P., Marre, M., Smithies,
O., and Alhenc-Gelas, F. (2001). Genetically increased angio-
tensin I-converting enzyme level and renal complications in
the diabetic mouse. Proc. Natl. Acad. Sci. USA 98,
13330–13334.
Kakoki, M., Kizer, C.M., Yi, X., Takahashi, N., Kim, H.S., Bagnell,
C.R., Edgell, C.J., Maeda, N., Jennette, J.C., and Smithies,
O. (2006). Senescence-associated phenotypes in Akita dia-
betic mice are enhanced by absence of bradykinin B2 recep-
tors. J. Clin. Invest. 116, 1302–1309.
Kakoki, M., McGarrah, R.W., Kim, H.S., and Smithies, O. (2007).
Bradykinin B1 and B2 receptors both have protective roles in
renal ischemia/reperfusion injury. Proc. Natl. Acad. Sci. USA
104, 7576–7581.
Leeb-Lundberg, L.M., Marceau, F., Muller-Esterl, W., Pettibone,
D.J., and Zuraw, B.L. (2005). International union of pharma-
cology. XLV. Classification of the kinin receptor family, from
molecular mechanisms to pathophysiological consequences.
Pharmacol. Rev. 57, 27–77.
Linz, W., Wiemer, G., Gohlke, P., Unger, T., and Scholkens, B.A.
(1995). Contribution of kinins to the cardiovascular actions of
angiotensin-converting enzyme inhibitors. Pharmacol. Rev.
47, 25–49.
Madeddu, P., Emanueli, C., and El-Dahr, S. (2007). Mechanisms
of disease, the tissue kallikrein-kinin system in hypertension
and vascular remodeling. Nat. Clin. Pract. Nephrol. 3, 208–
221.
Meneton, P., Bloch-Faure, M., Hagege, A.A., Ruetten, H., Huang,
W., Bergaya, S., Ceiler, D., Gehring, D., Martins, I., Salmon,
G., et al. (2001). Cardiovascular abnormalities with normal
blood pressure in tissue kallikrein-deficient mice. Proc. Natl.
Acad. Sci. USA 98, 2634–2639.
Messadi-Laribi, E., Griol-Charhbili, V., Pizard, A., Vincent, M.P.,
Heudes, D., Meneton, P., Alhenc-Gelas, F., and Richer, C.
(2007). Tissue kallikrein is involved in the cardioprotective
effect of AT1-receptor blockade in acute myocardial ische-
mia. J. Pharmacol. Exp. Ther. 323, 210–216.
Oldenburg, O., Qin, Q., Krieg, T., Yang, X.M., Philipp, S., Critz,
S.D., Cohen, M.V., and Downey, J.M. (2004). Bradykinin
induces mitochondrial ROS generation via NO, cGMP, PKG,
and mitoKATP channel opening and leads to cardioprotec-
tion. Am. J. Physiol. Heart Circ. Physiol. 286, H468–476.
Picard, N., Van Abel, M., Campone, C., Seiler, M., Bloch-Faure,
M., Hoenderop, J.G., Loffing, J., Meneton, P., Bindels, R.J.,
Paillard, M., et al. (2005). Tissue kallikrein-deficient mice dis-
play a defect in renal tubular calcium absorption. J. Am. Soc.
Nephrol. 16, 3602–3610.
Picard, N., Eladari, D., El Moghrabi, S., Planes, C., Bourgeois,
S., Houillier, P., Wang, Q., Burnier, M., Deschenes, G., Knep-
per, M.A., et al. (2008). Defective ENaC processing and func-
tion in tissue kallikrein-deficient mice. J. Biol. Chem. 283,
4602–4611.
Pons, S., Griol-Charhbili, V., Heymes, C., Fornes, P., Heudes, D.,
Loyer, X., Hagege, A., Meneton, P., Giudicelli, J., Alhenc-
Gelas, F., and Richer, C. (2008). Tissue kallikrein deficiency
aggravates cardiac remodeling and decreases survival after
myocardial infarction in mice. Eur. J. Heart Fail., in press.
DOI: 10.1016/j.ejheart.2008.02.002.
Rossi, G.P., Taddei, S., Ghiadoni, L., Virdis, A., Zavattiero, S.,
Favilla, S., Versari, D., Sudano, I., Azizi, M., Vedie, B., et al.
(2006). Tissue kallikrein gene polymorphisms induce no
change in endothelium-dependent or independent vasodila-
tion in hypertensive and normotensive subjects. J. Hyper-
tens. 24, 1955–1963.
Sato, M., Engelman, R.M., Otani, H., Maulik, N., Rousou, J.A.,
Flack, J.E. III, Deaton, D.W., and Das, D.K. (2000). Myocardial
protection by preconditioning of heart with losartan, an angio-
tensin II type 1-receptor blocker, implication of bradykinin-
dependent and bradykinin-independent mechanisms. Circu-
lation 102, III346–351.
Siragy, H.M., de Gasparo, M., and Carey, R.M. (2000). Angio-
tensin type 2 receptor mediates valsartan-induced hypoten-
sion in conscious rats. Hypertension 35, 1074–1077.
Slim, R., Torremocha, F., Moreau, T., Pizard, A., Hunt, S.C., Vua-
gnat, A., Williams, G.H., Gauthier, F., Jeunemaitre, X., and
Alhenc-Gelas, F. (2002). Loss-of-function polymorphism of
the human kallikrein gene with reduced urinary kallikrein
activity. J. Am. Soc. Nephrol. 13, 968–976.
Trabold, F., Pons, S., Hagege, A.A., Bloch-Faure, M., Alhenc-
Gelas, F., Giudicelli, J.F., Richer-Giudicelli, C., and Meneton,
P. (2002). Cardiovascular phenotypes of kinin B2 receptor-
and tissue kallikrein-deficient mice. Hypertension 40, 90–95.
Vallet, V., Chraibi, A., Gaeggeler, H.P., Horisberger, J.D., and
Rossier, B.C. (1997). An epithelial serine protease activates
the amiloride-sensitive sodium channel. Nature 389, 607–
610.
Wang, Q., Hummler, E., Nussberger, J., Clement, S., Gabbiani,
G., Brunner, H.R., and Burnier, M. (2002). Blood pressure,
cardiac, and renal responses to salt and deoxycorticosterone
acetate in mice, role of renin genes. J. Am. Soc. Nephrol. 13,
1509–1516.
Yang, X.P., Liu, Y.H., Mehta, D., Cavasin, M.A., Shesely, E., Xu,
J., Liu, F., and Carretero, O.A. (2001). Diminished cardiopro-
tective response to inhibition of angiotensin-converting
enzyme and angiotensin II type 1 receptor in B2 kinin receptor
gene knockout mice. Circ. Res. 88, 1072–1079.
Yu, H., Song, Q., Freedman, B.I., Chao, J., Chao, L., Rich, S.S.,
and Bowden, D.W. (2002). Association of the tissue kallikrein
gene promoter with ESRD and hypertension. Kidney Int. 61,
1030–1039.
Zhou, G.X., Chao, L., and Chao, J. (1992). Kallistatin, a novel
human tissue kallikrein inhibitor. Purification, characteriza-
tion, and reactive center sequence. J. Biol. Chem. 267,
25873–25880.
Zinner, S.H., Margolius, H.S., Rosner, B., Keiser, H.R., and Kass,
E.H. (1976). Familial aggregation of urinary kallikrein concen-
tration in childhood, relation to blood pressure, race and
urinary electrolytes. Am. J. Epidemiol. 104, 124–132.
